Treatment of Canakinumab and Tislelizumab in Combination with Nab-Paclitaxel and Gemcitabine up to 4 cycles (4 months)
250 mg subcutaneous injection in prefilled syringes on day 1 of every 28-day cycle
Other Name: ACZ885
300 mg in a liquid vial (concentrate for intravenous (i.v.) solution) on day 1 of every 28-day cycle
125 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
1000 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.